DWC202313, DWC202314

Phase 3Small molecule

Daewoong Pharmaceutical Co. LTD.

DWC202313, DWC202314 is one of 26 small molecule programs targeting Hypertension. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypertensionActive, not recruiting

HypertensionPhase 3

Active, not recruiting

Competition

Competitive Landscape

566 competitors in Hypertension

#DrugCompanyPhaseTrials

Apresoline

Novartis

Preclinical

7 2

Zebeta

Teva

Preclinical

6 3

Edarbi

Takeda

Preclinical

4 4

DWC202313, DWC202314

Daewoong Pharmaceutical Co. LTD.

Phase 3

1 5

Aceon

Institut de Recherches Internationales Servier

Preclinical

5 6

Alphagan

Winrevair

Deltavit

HHyundai Pharmaceutical Co., LTD.

Preclinical

2 9

Disalcid

JJoslin Diabetes Center

Preclinical

1 10

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tics1 trial

Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition.

Recruiting· Daewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.·Phase 1·NCT07267221·36 enrolled

Fasting Conditions1 trial

Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1622, DWC202313, and DWC202314 in Healthy Volunteers Under Fasting Conditions

Recruiting· Daewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.·Phase 1·NCT07260851·40 enrolled

Hypertension1 trial

A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension

Completed· Daewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.·Phase 3·NCT06671392·198 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for DWC202313, DWC202314. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DWC202313, DWC202314 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DWC202313, DWC202314. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Daewoong Pharmaceutical Co. LTD. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Daewoong Pharmaceutical Co. LTD.

DWC202313, DWC202314

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tics1 trial

Fasting Conditions1 trial

Hypertension1 trial

References

Drug Info

Quick Facts

Related News